Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA conference, From Cancer Discovery Science to Therapeutic Innovation, being held February 1-5, 2025 in Maui, Hawaii.
The talk, titled, 'KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment,' will be held on February 5, 2025 at 4:00 PM local time.
The American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) offer this 13th AACR-JCA Joint Conference. This meeting series has a long tradition of bringing together outstanding researchers from the United States, Japan, and around the world to share their findings and present the latest advances in basic, translational, and clinical cancer research.
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential' or 'hopes' or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Louie Toma
SOURCE: Kairos Pharma, Ltd
Copyright Business Wire 2025.
PUB: 01/28/2025 08:15 AM/DISC: 01/28/2025 08:15 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Equinox Gold Corp. (EQX) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Equinox Gold Corp. (NYSEAmerican:EQX) stands against other Friday's worst-performing stocks. Equinox Gold dropped its share prices by 5.06 percent on Friday to finish at $6.94 apiece as investors unloaded portfolios amid the drop in spot prices of gold. On the same day, gold saw its spot prices decline by 1.26 percent to $3,310.42 per troy ounce, amid a profit-taking from the previous day's gains. Aerial view of a large-scale gold mine, showing the extent of the company's operations. In recent news, Equinox Gold Corp. (NYSEAmerican:EQX) entered into an agreement with Calibre Mining Corp. for their planned $1.8-billion merger. Under the transaction, Equinox Gold Corp. (NYSEAmerican:EQX) will acquire all of Calibre's issued and outstanding shares. The transaction is expected to boost Equinox Gold Corp.'s (NYSEAmerican:EQX) producing mines to nine from seven previously, alongside Calibre's Valentine project in Newfoundland, which is underway construction. Upon completion, Equinox Gold Corp. (NYSEAmerican:EQX) is set to become Canada's largest gold miner. The transaction is expected to be closed this month. Overall, EQX ranks 5th on our list of Friday's worst-performing stocks. While we acknowledge the potential of EQX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Motor Trend
15 hours ago
- Motor Trend
Hyundai's Hydrogen Fuel Cell Technology - Episode 45
© 2025 MotorTrend | MOTOR TREND GROUP, LLC. ALL RIGHTS RESERVED. Hearst Autos, Inc. recently acquired the website and MotorTrend mobile application from Warner Bros. Discovery. During a transition period, your use of the website and mobile application will continue to be governed by the practices described in the Warner Bros. Discovery Privacy Policy and the Terms of Use
Business Wire
a day ago
- Business Wire
KNW Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Know Labs, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Know Labs, Inc. (NYSE American: KNW) to Goldeneye 1995 LLC is fair to Know Labs shareholders. Halper Sadeh encourages Know Labs shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Know Labs and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Know Labs shareholders; (2) determine whether Goldeneye is underpaying for Know Labs; and (3) disclose all material information necessary for Know Labs shareholders to adequately assess and value the merger consideration. On behalf of Know Labs shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
